Diabetes drug Ozempic can reduce severe liver disease risk too
London, Jan 24 (IANS) Novo Nordisk's Ozempic and other GLP1 agonists -- popular diabetes drugs -- are also associated with a reduced risk of developing cirrhosis and liver cancer in people with Type 2 diabetes and chronic liver disease, according to a study.